2008 Chicago Multidisciplinary Symposium in Thoracic Oncology
Click here to go to the previous page
General Session XVI: Outcome Measures: Imaging
Program Code:
220
Date:
Saturday, November 15, 2008
SPEAKER(S):
Click the plus sign to see more detailed information
about each speaker.
Feng-Ming Kong,
M.D., Ph.D., M.P.H, Radiation Oncologist,
University of Michigan
|
Dr. Feng-Ming (Spring) Kong completed medical school and a doctoral program at Fudan University, in Shanghai, followed by a post-doctorate fellowship in translational scientific research at Duke University Medical Center, in Durham, N.C. She then received clinical training in radiation oncology at Washington University in St. Louis and was certified by the American Board of Radiology in radiation oncology. In 2003, Dr. Kong joined the faculty of the University of Michigan, where she currently coordinates lung research studies in the Department of Radiation Oncology with an emphasis on functional image-guided, individualized high-dose radiation therapy. Dr. Kong's research interests include designing and conducting clinical trials to improve treatment results for lung cancer patients and testing molecular biomarkers in patients' blood for radiation induced lung toxicity. She is currently participating in a clinical trial design and data analysis program through the U-M School of Public Health. Dr. Kong's clinical interests include radiation therapy and the care of treatment-related toxicities in lung cancer patients as well as patients with other thoracic malignancies.
|
Quynh-Thu Le, M.D., Professor, Stanford School of Medicine
|
I am a Radiation Oncologist with a strong interest in clinical and translational research. After initial training in Internal Medicine and Clinical Oncology the UK, I spent two years on the Faculty at the Department of Radiation Oncology at Stanford University|University before taking up my current position as Radiation Oncologist at Peter MacCallum Cancer Centre. I am an Associate Professor at the |University of Melbourne and Chair the RANZCR Research Committee in Radiation Oncology. One of my major interests has been the role of PET scanning in patients who are candidates for Radiation Therapy. In collaboration with my colleague Professor Rod Hicks I have been involved in some of the first prospective studies of PET in Radiation Oncology and together we have published many papers on this topic. Current interests include RT planning using FDG-PET and studying changes in FLT uptake during the course of RT. Recent publications concern the role of FDG-PET in staging lung cancer, response assessment after chemo RT and the role of PET in RT planning. I am a member of the IAEA group that has studied PET in RT planning and we hope that our report will be published in the near future.
|
|
J.P. Sculier, MD, Ph D, is currently chief of medical intensive care and lung cancer clinic at the Institute Jules Bordet (ULB, Brussels, Belgium). President of the European Lung Cancer Working Party and co-ordinator of the clinical trials of this cooperative group, he is the author of multiple publications on lung cancer with a special expertise in thoracic oncology. He is professor of internal medicine at the University of Brussels.
|
|
Professor Johan Vansteenkiste is Associate Professor of Internal Medicine in the Faculty of Medicine at the Catholic University of Leuven, Belgium, and Head of Clinic in the Respiratory Oncology Unit and its Clinical Trial Unit at the Leuven University Hospital.
Professor Vansteenkiste studied Medicine at the Catholic University of Leuven before becoming a Board Certified Pulmonologist-Oncologist. He had additional training in Respiratory Oncology at the European School of Oncology in Milan, Italy, and in Respiratory Endoscopy at the Laser Centre in Marseille, France, before gaining his PhD at the Catholic University of Leuven in 1996.
Professor Vansteenkiste is an active member of many different national and international societies such as IASLC, ASCO, ESMO, ERS and others. He was Secretary of the Thoracic Oncology Group of the European Respiratory Society from 1999-2003, and currently Secretary of the ERS Clinical Assembly and board member of the ERS School.
He is the principal investigator or co-investigator in several clinical trials in the area of lung cancer. He is Associate Editor at the Journal of Thoracic Oncology, member of the editorial board of the Journal of Clinical Oncology and other journals, and author or co-author of more than 140 peer-reviewed papers and book chapters on Respiratory Oncology.
He is the recipient of several awards, including the ‘Eli-Lilly L. Hertel Chair in Respiratory Oncology’, the ‘Amgen Chair in Supportive Cancer Care’, and the ‘Hoffman-Roche Chair in Molecular Targeted Cancer Therapy’ at the Catholic University of Leuven.
|
